Edition:
Deutschland

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

5,600JPY
07:00 Uhr
Change (% chg)

¥20 (+0.36%)
Prev Close
¥5,580
Open
¥5,600
Day's High
¥5,630
Day's Low
¥5,550
Volume
727,300
Avg. Vol
919,597
52-wk High
¥6,080
52-wk Low
¥3,660

4519.T

Chart for 4519.T

About

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as... (more)

Buy/Sell

Sell Hold Buy
2.23 Mean rating from 13 analysts

Overall

Beta: 0.64
Market Cap(Mil.): ¥2,650,113.00
Shares Outstanding(Mil.): 559.69
Dividend: 29.00
Yield (%): 1.16

Swiss stocks - Factors to watch on Jan 19

ZURICH, Jan 19 The Swiss blue-chip SMI was seen opening 0.13 percent lower at 9,440 points on Friday, according to premarket indications by bank Julius Baer .

BRIEF-CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order

* Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd

BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei‍​

* CHUGAI PHARMACEUTICAL LOOKS TO INVEST SOME 25 BILLION YEN INTO A SINGAPORE RESEARCH CENTER FOR BIOPHARMACEUTICALS BY 2021 - NIKKEI‍​ Source text :(s.nikkei.com/2CitZyn) Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-Chiome Bioscience says termination of joint research contract

* Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD, as the contract has expired on Dec. 31

BRIEF-Chugai Pharmaceutical says change of chief executive officer

* Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018

BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I

Roche's Chugai transfers rights of 13 Long-Term Listed Products to Taiyo

ZURICH, Nov 14 Chugai Pharmaceuticals, a Japan-based Roche subsidiary, said on Tuesday it has agreed to transfer the marketing and manufacturing right of 13 long-term listed products to Taiyo Holdings' Taiyo Pharma.

BRIEF-Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma

* Says it and TAIYO HOLDINGS CO LTD announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings

BRIEF-Chugai Pharma considering selling production rights of some medications to Taiyo - Nikkei

* Chugai Pharma considering selling production, sales rights of some 15 medications with expired patents to Taiyo Holdings for about 20 billion yen - Nikkei Source text : (http://s.nikkei.com/2iRwewI) Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.29%
Rohstoffe -0.33%
Industrie -0.26%
Konjunktur abhängige Waren & Dienstleistungen -0.23%
Konjunktur unabhängige Waren & Dienstleistungen -0.17%
Finanzindustrie -0.06%
Pharma -0.06%
Technologie -0.11%
Telekommunikation -0.06%